Zacks Investment Research maintains a Hold rating on Cooper Companies, citing growth in premium contact lenses and operational restructuring, while near-term headwinds persist. CooperVision's premium lens migration and MiSight myopia-management leadership are driving performance, with MyDay daily silicone hydrogel lenses achieving double-digit growth and MiSight growing 23%. The company posted a 20% increase in adjusted earnings per share as operating expenses declined, reflecting durable operating leverage from last year's restructuring. However, challenges include weakness in Japan's Asia-Pacific segment, competitive pressure on legacy hydrogel products, and ongoing uncertainty in CooperSurgical's fertility business, particularly in China and the Middle East. Shares have lost 13.8% year-to-date, underperforming the industry's 2% decline and the S&P 500's 10.3% rise.
The Cooper Companies, IncPremium lens migration and MiSight myopia-management leadership driving performance, with MyDay double-digit growth and MiSight 23% growth.
Align Technology Inc
Cardinal Health Inc
Intuitive Surgical Inc